Research programme: Baculovirus gene delivery systems - Ark Therapeutics

Drug Profile

Research programme: Baculovirus gene delivery systems - Ark Therapeutics

Alternative Names: BacV

Latest Information Update: 16 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ark Therapeutics
  • Class Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 09 Sep 2010 Discontinued - Preclinical for Undefined indication in Finland (unspecified route)
  • 17 May 2010 Preclinical development is ongoing in Finland
  • 05 Feb 2007 Preclinical trials in Age-related macular degeneration in Finland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top